Skip to main content
Equibles

Andrew Phillips, Ph.D.

Board Member

Enliven Therapeutics, Inc. (ELVN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Enliven Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ELVN alerts

About Andrew Phillips, Ph.D.

Andrew Phillips, Ph.D. is recorded as Board Member at Enliven Therapeutics, Inc. (ELVN) since February 23, 2023. Enliven Therapeutics, Inc. reported in an 8-K filed January 7, 2026 that Andrew Phillips, Ph.D. resigned as director, effective January 7, 2026. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Andrew Phillips, Ph.D. was appointed Board, effective February 23, 2023. Enliven Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enliven Therapeutics, Inc. includes Richard Fair (CEO and Board Member), Rick Fair (CEO and Board Member), Sam Kintz, M.B.A. (CEO and Board Member) and 7 others.

“On January 6, 2026, Andrew Phillips, Ph.D. informed the Board that he was resigning from the Board, the Audit Committee of the Board and the Nominating Committee, effective on January 7, 2026.”
Enliven Therapeutics, Inc. Form 8-K, filed January 7, 2026 · Read the filing
“Pursuant to the Merger Agreement, as of the effective time of the Merger, the size of the Board was fixed at nine members consisting of one member designated by the Company, Dr. Ballal, and all eight members of the board of directors of Former Enliven, namely Sam Kintz, M.B.A., Joseph Lyssikatos, Ph.D., Jake Bauer, Mika Derynck, M.D., Rishi Gupta, J.D., Richard Heyman, Ph.D., Andrew Phillips, Ph.D., and Andrew Schwab.”
Enliven Therapeutics, Inc. Form 8-K, filed March 1, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Enliven Therapeutics, Inc.

Recent activity